Holen Sie sich die Stockscreener-App
0.943
3.78%
-0.037
Schlusskurs vom Vortag:
$0.98
Offen:
$0.9808
24-Stunden-Volumen:
264.04K
Relative Volume:
0.79
Marktkapitalisierung:
$42.48M
Einnahmen:
$1.12M
Nettoeinkommen (Verlust:
$-11.17M
KGV:
-2.9832
EPS:
-0.3161
Netto-Cashflow:
$-10.98M
1W Leistung:
-11.87%
1M Leistung:
+19.34%
6M Leistung:
-29.63%
1J Leistung:
+6.99%
1-Tages-Spanne:
$0.92
$1.0199
1-Wochen-Bereich:
$0.92
$1.10
52-Wochen-Spanne:
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
Firmenname
Renovorx Inc
Sektor
Branche
Telefon
408-800-2649
Adresse
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.943 | 44.15M | 1.12M | -11.17M | -10.98M | -0.3161 |
VRTX
Vertex Pharmaceuticals Inc
|
433.63 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.48 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.68 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.95 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.56 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
RNXT Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Yahoo Finance
Street Watch: How does RenovoRx Inc perform in inflationary periods2026 Price Action Summary & Reliable Price Breakout Signals - baoquankhu1.vn
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial - The Globe and Mail
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
RenovoRx Reports Solid First Full Year of RenovoCath Commercialization - National Today
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Trade Recap: What chart patterns are forming on RenovoRx IncMarket Performance Summary & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Published on: 2026-03-31 14:32:17 - baoquankhu1.vn
RNXT: 2026 revenue is projected to triple as commercial site expansion accelerates and funding strengthens - TradingView
RNXT: 2025 revenue reached $1.1M, with 2026 guidance of $3–$4M and rapid commercial site expansion - TradingView
Earnings call transcript: RenovoRx Q4 2025 results show revenue growth - Investing.com
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update - Investing News Network
RNXT: 2025 revenue rose to $1.1M, but net loss increased as commercialization and R&D spending grew - TradingView
RenovoRx (NASDAQ: RNXT) surges 2025 revenue and advances Phase III TIGeR-PaC - Stock Titan
RenovoRx (NASDAQ: RNXT) grows RenovoCath use and advances Phase III TIGeR-PaC - Stock Titan
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
RNXT: 2025 revenue reached $1.1M as RenovoCath adoption expanded; TIGER-PAC trial nears completion - TradingView
RenovoRx, Inc. (RNXT) Q4 FY2025 earnings call transcript - Yahoo Finance
RenovoRx 2025 net loss widens on higher operating expenses - TradingView
BRIEF-RenovoRx FY Net Income USD -11.168 Million - TradingView
Cancer device reaches 12 U.S. centers as RenovoRx readies trial finish - Stock Titan
RenovoRx Q4 2025 Earnings Call Transcript - MarketBeat
Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 Result - gurufocus.com
RenovoRx Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
RenovoRx (RNXT) CFO granted 12,380 RSUs, now reports 134,580 shares - Stock Titan
RenovoRx (RNXT) CFO discloses 25,000 shares bought pre-role - Stock Titan
RenovoRx appoints Dr. Ramtin Agah as executive chairman and updates compensation - Investing.com
[8-K] RenovoRx, Inc. Reports Material Event - Stock Titan
RenovoRx, Inc. Appoints Ramtin Agah, M.D. As Executive Chairman , Effective February 27, 2026 - marketscreener.com
RenovoRx surpasses 100 patients in Phase III pancreatic trial By Investing.com - Investing.com South Africa
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment - Investing News Network
Sell Signal: Is RenovoRx Inc stock a value trapInsider Selling & Smart Swing Trading Alerts - baoquankhu1.vn
RenovoRx surpasses 100 patients in Phase III pancreatic trial - Investing.com
RenovoRx pancreatic cancer trial passes 100 patients, 2027 data next - Stock Titan
RenovoRx CFO voll acquires shares and warrants in RNXT By Investing.com - Investing.com Australia
RenovoRx CFO voll acquires shares and warrants in RNXT - Investing.com
Laurence Marton buys RenovoRx stock and warrants for $10,000 By Investing.com - Investing.com Australia
Shaun Bagai, CEO of Renovorx, buys $0 of RNXT stock By Investing.com - Investing.com Australia
Shaun Bagai, CEO of Renovorx, buys $0 of RNXT stock - Investing.com
Laurence Marton buys RenovoRx stock and warrants for $10,000 - Investing.com
RenovoRx (RNXT) executive discloses direct ownership of 25,000 shares - Stock Titan
RenovoRx (RNXT) director adds $10K via rollover IRA private deal - Stock Titan
The most innovative companies in medical devices of 2026 - Fast Company
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement - Investing News Network
RenovoRx Raises $10 Million in Oversubscribed Private Placement - TipRanks
RenovoRx Secures $10 Million Oversubscribed Private Placement to Accelerate RenovoCath Commercialization and Advance Phase III Pancreatic Cancer Trial - Minichart
Trend Recap: Can RenovoRx Inc expand its profit margins2026 Year in Review & Growth Focused Entry Reports - baoquankhu1.vn
RenovoRx Raises ~$10 Million in Private Placement; Sells Stock and Warrants at $0.938 Per Share - TradingView
Finanzdaten der Renovorx Inc-Aktie (RNXT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Renovorx Inc-Aktie (RNXT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Dec 31 '25 |
Buy |
0.86 |
9,795 |
8,424 |
788,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
| Bagai Shaun | Chief Executive Officer |
Aug 22 '25 |
Buy |
0.95 |
5,000 |
4,748 |
325,040 |
| Bagai Shaun | Chief Executive Officer |
Aug 25 '25 |
Buy |
0.91 |
5,000 |
4,549 |
330,040 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):